Polatuzumab vedotin-piiq 30 mg
RxNorm 2398130

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2398130 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: polatuzumab vedotin-piiq 30 mg.

The following semantic concepts and normalized strings are associated with this clinical entity:

SCDC
Polatuzumab vedotin-piiq 30 mg
AUI:12439820
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SCDCPrescribable

Semantic Clinical Drug Component (SCDC):
Polatuzumab vedotin-piiq 30 mg
(Atom ID: 12439820)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
polatuzumab vedotin-piiq 30 MG
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2398130
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12439820
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SCDC
Semantic Clinical Drug Component (Ingredient + Strength)
Source Code
2398130
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN BOSS STRENGTH DENOM UNIT
1
RXN Boss Strength Denom Unit
RXN BOSS STRENGTH DENOM VALUE
1
RXN Boss Strength Denom Value
RXN BOSS STRENGTH NUM UNIT
MG
RXN Boss Strength Num Unit
RXN BOSS STRENGTH NUM VALUE
30
RXN Boss Strength Num Value
RXN STRENGTH
30 MG
Strength plus unit of SCDC

Patient Education

Polatuzumab vedotin-piiq Injection


Polatuzumab vedotin-piiq injection is used along with bendamustine (Belrapzo, Treanda) and rituximab (Rituxan) in adults to treat a certain type of non-Hodgkin's lymphoma (NHL; a type of cancer that begins in a type of white blood cells that normally fights infection) that did not improve or improved but returned after treatment with at least two other chemotherapy medications. Polatuzumab vedotin-piiq is in a class of medications called antibody-drug conjugates. It works by killing cancer cells.
[Learn More]


* Please review the disclaimer below.